Plain-English translation of NCT05967949 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
This is a retrospective study, which means researchers are looking back at medical records from patients who have already been treated. The study focuses on , a medication used to help keep peripheral T-cell lymphoma (a type of blood cancer) under control after initial treatment. Researchers want to understand how safe and effective this medication is as a long-term maintenance therapy for this condition.
Peripheral T-cell lymphoma is a rare and difficult-to-treat blood cancer. This study exists to better understand whether this medication works well over time as a maintenance therapy โ meaning whether it helps keep the cancer from coming back after the first round of treatment.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you join this study, researchers will review your existing medical records โ including your age, gender, previous treatments, blood tests, imaging scans (like PET-CT), and other test results. This is not a study where you receive new treatment; instead, the research team is studying information from your past care to learn more about how well the medication worked for you. There are no additional visits or procedures required beyond what you may already be doing as part of your regular cancer care.
AI-generated summary from trial data ยท Nov 17, 2026 ยท Not medical advice
China
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Enrollment target
~200 participants
Started
April 2023
Primary completion
April 2026
This trial's estimated completion date has passed โ the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2023.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
wei xu
The First Affiliated Hospital with Nanjing Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.